Home » Stocks » Esperion Therapeutics

Esperion Therapeutics, Inc. (ESPR)

Stock Price: $38.00 USD -0.57 (-1.48%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $39.18 +1.18 (3.11%) Aug 7, 7:31 PM

Stock Price Chart

Key Info

Market Cap 1.05B
Revenue (ttm) 4.79M
Net Income (ttm) -262.79M
Shares Out 27.62M
EPS (ttm) -9.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $38.00
Previous Close $38.57
Change ($) -0.57
Change (%) -1.48%
Day's Open 38.49
Day's Range 37.94 - 39.11
Day's Volume 645,608
52-Week Range 24.82 - 76.98

More Stats

Market Cap 1.05B
Enterprise Value 1.06B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.62M
Float 25.10M
EPS (basic) -9.66
EPS (diluted) -9.64
FCF / Share -8.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.13M
Short Ratio 16.98
Short % of Float 44.21%
Beta 1.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 219.32
PB Ratio 60.92
Revenue 4.79M
Operating Income -254.48M
Net Income -262.79M
Free Cash Flow -232.33M
Net Cash -9.10M
Net Cash / Share -0.33
Gross Margin -569.43%
Operating Margin -5,318.20%
Profit Margin -5,492.00%
FCF Margin -4,855.46%
ROA -76.44%
ROE -421.26%
ROIC -219.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 9
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(130.87% upside)
Current: $38.00
Target: 87.73
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit148--------
Operating Income-93.10-205-169-76.15-50.04-36.22-22.76-10.20-10.16
Net Income-97.17-202-167-74.98-49.78-36.38-26.09-11.74-10.82
Shares Outstanding27.0926.7523.9322.5422.0216.377.890.320.30
Earnings Per Share-3.59-7.54-6.98-3.33-2.26-2.22-3.31-36.31-36.22
Operating Cash Flow-70.34-149-131-47.73-38.16-32.02-18.11-10.81-9.07
Capital Expenditures-0.95-0.15-0.02-0.09-0.30-0.860.17-0.01
Free Cash Flow-71.29-149-131-47.82-38.46-32.88-17.94-10.81-9.06
Cash & Equivalents20213620021221210660.066.511.57
Total Debt134-1.052.734.294.87-22.776.90
Net Cash / Debt67.6013619920920810160.06-16.26-5.33
Book Value19.9579.1224522928713474.09-41.36-30.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Esperion Therapeutics, Inc.
Country United States
Employees 193
CEO Tim M. Mayleben

Stock Information

Ticker Symbol ESPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ESPR
IPO Date June 26, 2013


Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.